The Biopharmaceutical Corporation reported its Q4 and FY2014 highlights on 30th March, supplemented by a conference call the following day. The conference call highlighted the progress that the company has made in its clinical pipeline as well setting out further steps it is taking to progress its candidates, new indications and further plasma protein derived therapeutics.
07 Apr 2015
Full year results conference call reveals expansion to clinical program
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Full year results conference call reveals expansion to clinical program
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
07 Apr 2015 -
Author:
Derren Nathan -
Pages:
7
The Biopharmaceutical Corporation reported its Q4 and FY2014 highlights on 30th March, supplemented by a conference call the following day. The conference call highlighted the progress that the company has made in its clinical pipeline as well setting out further steps it is taking to progress its candidates, new indications and further plasma protein derived therapeutics.